Clinical Trials Update: July 19, 2007
Osteoarthritis Social Anxiety Disorder (SAD) Gastroesophageal Reflux Disease (GERD)
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study is for people with active osteoarthritis of the knee. Some participants will take an oral dose of the study drug along with a NSAID, and results will be compared with others who took and non-medicinal placebo. Participants must be ages 50 to 75 and diagnosed with osteoarthritis of the knee for at least three months, confirmed by X-ray.
The research site is in Wichita, Kans.
Social Anxiety Disorder (SAD)
This study will evaluate the effectiveness of paroxetine (Paxil) treatment on brain activation patterns among people with social anxiety disorder. Psychiatric and medical evaluations will be administered to determine eligibility. Participants must be ages 18-65, have SAD, and cannot currently be taking psychiatric medication.
The research site is in New York City.
Gastroesophageal Reflux Disease (GERD)
The study will evaluate a once-daily dose of esomeprozole (Nexium) in reducing symptoms of gastroesophageal reflux disease (GERD) in infants. To participate, a parent must sign an informed consent document before the study, and infants must be diagnosed with suspected or confirmed GERD.
The research site is in Chattanooga, Tenn.
Copyright 2007 Thomson CenterWatch. All rights reserved.